www.fdanews.com/articles/82401-aeterna-reports-steeper-third-quarter-loss
AETERNA REPORTS STEEPER THIRD-QUARTER LOSS
November 14, 2005
Aeterna Zentaris Inc. (AEZ.TO: Quote, Profile, Research) reported a steeper third-quarter loss on Monday after higher revenue from acquisitions was offset by a stronger Canadian dollar. The Canadian biotech company said it lost C$4.8 million ($4 million), or 10 Canadian cents a share, in the latest period, compared with a loss of C$2 million, or 4 Canadian cents a share, in the same period last year. Revenue was C$63.4 million for the quarter, up from C$55.4 million in the same quarter last year. Aeterna attributed the increase in revenue to two recent acquisitions -- Echelon Biosciences and Multichem.